Zeleciment rostudirsen (z-rostudirsen)

Name: Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Gene therapy
Published: 2026-09-14T15:39:06-04:00

Duchenne muscular dystrophy

Also known as DYNE-251

Manufacturer: Dyne Therapeutics
Regulatory submission: BLA submitted May 2026
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Gene therapy

1 evidence topic · 1 source

Treatment alternatives: delandistrogene moxeparvovec-rokl

“ambulatory patients four years of age and older” (opens the source at this quote in a new tab)
“Boxed Warning” (opens the source at this quote in a new tab)
“risk of serious liver injury and acute liver failure, including fatal outcomes” (opens the source at this quote in a new tab)